摘要
目的：测定不同基质、不同主药浓度、不同渗透促进剂的各种软膏中他巴唑及氢化可的松的体外透皮释药率，评价各因素对主药经皮渗透的影响。方法：用改良Ｆｒａｎｚ垂直扩散池，ＨＰＬＣ测定。结果：Ａ型、Ｂ型基质软膏中，他巴唑的透皮释药率分别为４９．１０％，２９．８３％（Ｐ＜０．０５）；氢化可的松的透皮释药率分别为３．１７％，１．５９％（Ｐ＜０．０５）。有或无月桂氮酮的软膏中，他巴唑的透皮释药率分别为４９．１０％，５４．１４％（Ｐ＞０．０５），氢化可的松的透皮释药率分别为３．１７％，１．６１％（Ｐ＜０．０５）。结论：ｏ／ｗ型基质较ｗ／ｏ型基质更有利于他巴唑及氢化可的松的经皮渗透。月桂氮酮对他巴唑无明显的促进渗透作用，但可提高氢化可的松的经皮渗透率１．９２倍。
To determine the percutaneous release of methimazole and hydrocortson in different stroma,permeation enhancers,their consistency in vitro,and evaluate the factors affecting drug release,METHOD:The vertical Franz diffusion cell was applied.The samples were analyzed by HPLC. RESULTS:In stroma A and B,the release rate of methimazole was 49.10%and 29.83%(P<0.05)respectively. In stroma A and B,the release rate of hydrocortison was 3. 17%and l.59%(P<0.05)respectively.In the ointment with laurocapram or without laurocapram,the release rate of methimazole was 49.10%and 54.15%(P>0.05),respectively. In the ointment with laurocapram or without,the release rate of hydrocortison was 3.17%and l.61%(P<0.05)respectively.CONCLUSION:Stroma o/w was more beneficial to the percutaneous permeation of the drug than stroma w/o. The effect of laurocapram was not obvious for methimazole.The laurocapram had certain penetrative accelerating effect on hydrocortison,and could raise the release rate for l.92 times.
出处
《中国药学杂志》
CAS
CSCD
北大核心
1996年第3期148-150,共3页
Chinese Pharmaceutical Journal
